Study | Design | Procedure | RS | Sample Size | MINORS score | Primary Outcomes |
---|---|---|---|---|---|---|
Trinh et al., 2021 [10] | Prospective | THA, TKA | BRS | 98 | 19 | PROMIS-10 |
Trinh et al., 2022 [13] | Retrospective | THA, TKA | BRS | 119 | 19 | Opioid Consumption |
Zabat et al., 2022 [14] | Retrospective | THA | BRS | 393 | 19 | HOOS, JR |
Bumberger et al., 2022 [15] | Prospective | THA | CD-RISC | 103 | 17.5 | WOMAC and UCLA score |
Magaldi et al., 2019 [11] | Prospective | TKA | BRS | 153 | 21 | KOOS, JR and PROMIS-10 |
Lynskey et al., 2021 [16] | Prospective | THA, TKA | CD-RISC | 140 | 22 | Satisfaction VAS and NPS |
March et al., 2022 [17] | Prospective | TKA | BRS | 75 | 21 | WOMAC and NPRS (Primary outcome was acute hospital LOS) |
Bumberger et al., 2021 [18] | Prospective | TKA | CD-RISC | 163 | 20 | WOMAC and UCLA score |
Nwankwo et al., 2021 [19] | Prospective | TKA | BRS | 117 | 21 | KOOS, JR and PROMIS Physical Health/Mental Health |
Benditz et al., 2017 [20] | Prospective | THA | RS-11 | 50 | 17 | HHS |
Haffar et al., 2021 [21] | Retrospective | TKA | BRS | 86 | 18.5 | KSS, KOOS, JR and VR-12 MCS |
Sciume et al., 2018 [22] | Prospective | THA, TKA | RS-10 | 80 | 16.5 | FIM; WHOQOL-BREF |